RESUMO
Bradykinin mediated angioedema (BK-AE) can be associated either with C1Inhibitor deficiency (hereditary and acquired forms), either with normal C1Inh (hereditary form and drug induced AE as angiotensin converting enzyme inhibitors ). In case of high clinical suspicion of BK-AE, C1Inh exploration must be done at first: C1Inh function and antigenemy as well as C4 concentration. C1Inh deficiency is significant if the tests are below 50 % of the normal values and controlled a second time. In case of C1Inh deficiency, you have to identify hereditary from acquired forms. C1q and anti-C1Inh antibody tests are useful for acquired BK-AE. SERPING1 gene screening must be done if a hereditary angioedema is suspected, even if there is no family context (de novo mutation 15 %). If a hereditary BK-AE with normal C1Inh is suspected, F12 and PLG gene screening is suitable.
Assuntos
Angioedemas Hereditários/metabolismo , Bradicinina/metabolismo , Proteína Inibidora do Complemento C1/análise , Algoritmos , Angioedema/induzido quimicamente , Angioedema/metabolismo , Angioedemas Hereditários/classificação , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Criança , Comorbidade , Proteína Inibidora do Complemento C1/genética , Diagnóstico Precoce , Fator XII/fisiologia , Feminino , Fibrinolisina/fisiologia , Doenças Hematológicas/epidemiologia , Angioedema Hereditário Tipos I e II/diagnóstico , Angioedema Hereditário Tipos I e II/metabolismo , Humanos , Calicreínas/fisiologia , Lúpus Eritematoso Sistêmico/epidemiologia , Gravidez , Complicações na Gravidez/sangue , Avaliação de SintomasRESUMO
Transformation of Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs) to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is associated with poor response to chemotherapy and short survival. Fifty-four patients with Ph-negative MPN (including 21 essential thrombocythemia [ET], 21 polycythemia vera [PV], 7 primary myelofibrosis, and 5 unclassified MPN) who had progressed to AML (n = 26) or MDS (n = 28) were treated with azacitidine in a patient-named program. Overall response rate was 52% (24% complete response [CR], 11% partial response [PR], 8% marrow CR or CR with incomplete recovery of cytopenias, 9% hematologic improvement) and median response duration was 9 months. Prognostic factors were for overall response the underlying MPN (71% vs 33% responses in ET and PV, respectively; P = .016); prognostic factors for CR achievement were the underlying MPN (14% CR for PV vs 43% for ET; P = .040) and World Health Organization classification at transformation (36% vs 12% CR in MDS and AML, respectively, P = .038). Recurrence of chronic phase features of the initial MPN was observed in 39% of the responders. Median overall survival was 11 months. Azacitidine gives encouraging results in Ph-negative MPN having progressed to AML or MDS, but response duration is short, and consolidation treatments have to be evaluated.